When was ReqMed founded?

ReqMed was founded in 1998 and raised its 1st funding round 25 years after it was founded.

Where is ReqMed located?

ReqMed is headquartered in Machida, Japan.

Is ReqMed a funded company?

ReqMed is a funded company, having raised a total of $***** in its 1st and only funding round, a Seed round on Sep 29, 2023.

When was the latest funding round of ReqMed?

ReqMed's latest funding was a $***** Seed round on Sep 29, 2023, with participation from 1 investor.

Where does ReqMed rank among its competitors?

ReqMed ranks 355th amongst 1030 active competitors, of which 64 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was Ipsen, which secured $618K in Dec, 2023.

Who are the top competitors of ReqMed?

ReqMed's top competitors include Precision Medicine Group, WuXi AppTec and ANI Pharmaceuticals. Among them, Ipsen secured the most recent funding round in December, 2023.

ReqMed - 2026 Company Profile, Funding & Competitors

ReqMed is a seed company based in Machida (Japan), founded in 1998. It operates as a Provider of drug development, consulting, and venture funding services. ReqMed has raised an undisclosed amount in funding. The company has 1030 active competitors, including 64 funded and 123 that have exited. Its top competitors include companies like Precision Medicine Group, WuXi AppTec and ANI Pharmaceuticals.

Company Details

Website: reqmed.co.jp
Phone Number: +81 **********

Key Metrics

Founded Year

1998

Location

Machida, Japan

Stage

Seed

Latest Funding Round

Seed, Sep 29, 2023, $*****

Investors

Mitsubishi UFJ Capital

Ranked

355^th among 1030 active competitors

Investment & Acquisitions

Agensys

Similar Companies

Precision Medicine Group & 1074 more

View ReqMed's full profile

ReqMed has raised funding over 1 round. Its latest funding round was a Seed round on Sep 29, 2023 for $*****. 1 investor participated in its latest round. ReqMed has 1 institutional investor.

Here is the list of recent funding rounds of ReqMed:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Sep 29, 2023	3047591	Seed	7271289	8226176	4920447	2111940

Access funding benchmarks and valuations. Sign up today!

View details of ReqMed's funding rounds and investors

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of ReqMed include Precision Medicine Group, WuXi AppTec and ANI Pharmaceuticals. Here is the list of Top 10 competitors of ReqMed, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Precision Medicine Group 2012, Bethesda (United States), Late Stage	Provider of clinical research, development, and commercialization services for life sciences	$532M	TPG, Oak Investment Partners & 7 others	71/100
2nd	WuXi AppTec 2000, Shanghai (China), Public	Provider of CRO and CDMO services	$40M	Synergis Capital, HongShan & 27 others	70/100
3rd	ANI Pharmaceuticals 1996, Baudette (United States), Public	Pharmaceutical company developing, manufacturing, and marketing high quality branded and generic prescription drugs	-	US Bank, Ampersand Capital & 4 others	63/100
4th	Aptar 1992, Crystal Lake (United States), Public	Provider of regulatory support, brand differentiation, and prototyping services	-	Al Zayani Investments	63/100
5th	Avania 1988, Brunswick (Australia), Acquired	Provider of regulatory, clinical trials and analytic services	-	Kester Capital, Omnes Capital & 1 others	63/100
6th	Eurofins Scientific 1987, Luxembourg (Luxembourg), Public	Provider of laboratory testing services and CRO contract research services	-	CDPQ, Holland Capital & 1 others	57/100
7th	Red Nucleus 2014, Yardley (United States), Acquired	Provider of advisory, scientific and medical communications for pharmaceutical industry	-	Maranon Capital, Renovus Capital Partners	57/100
8th	Ipsen 1929, Paris (France), Public	Biopharmaceutical company focused on developing and commercializing innovative treatments in oncology, rare disease, and neuroscience to improve patient health outcomes	-	Digital Pharma Lab, PAI Partners & 2 others	57/100
9th	CHEPLAPHARM 1998, Mesekenhagen (Germany), Late Stage	Pharmaceutical company that specializes in the development, marketing, and distribution of branded pharmaceutical products	$547M	GIC, Atlantic Park & 4 others	56/100
10th	Isolere Bio 2017, Durham (United States), Acquired	Developer of bioprocessing reagents for purification and manufacturing of therapeutics	$7M	Northpond Ventures, NCBiotech & 2 others	56/100
355th	ReqMed 1998, Machida (Japan), Seed	Provider of drug development, consulting, and venture funding services	-	Mitsubishi UFJ Capital	26/100